Comparison of topical 0.03% tacrolimus with 0.05% clobetasol in treatment of vitiligo
Abstract
Objective Tocompare the efficacy and safety of topical tacrolimus ointment with topical clobetasol ointment in vitiligo patients.Methods This quasi-experimental study was carried out in outpatient, Department of Dermatology Unit-II, KMEU/ Mayo Hospital, Lahore. Sixty patients above 12 years were selected by nonprobability purposive sampling method and were divided into two equal groups. Patients having lesions of less than 2 years of duration were included. After obtaining an informed consent, patients in group I were treated with twice daily application of 0.1% tacrolimus ointment and group II with clobetasol ointment for a period of six months. If no response was obtained, treatment was stopped after three months.Results Repigmentation was seen in 15 (50%) patients in tacrolimus group and 27 (90.0%) in clobetasol group. Contact dermatitis was noted in one patient in each group and acneiform eruption was recorded in one patient in the clobetasol group.Conclusion Topically, clobetasol remains to be an effective therapy in vitiligo. Topical tacrolimus was not effective in our patients. Intermittent use of clobetasol is as safe as continuous use of tacrolimus.References
Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesisf of vitiligo. Pigment Cell Res. 2003;16:90- 100.
Laberge G, Mailloux CM, Gowan K, Holland P, Bennett DC, Fain PRet al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo.Pigment Cell Res. 2005;18:300-5.
Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16:208-14.
Esposito M, Soda R, Costanzo A, Chimenti S. Treatment of vitiligo with the 308nm excimer laser. Clin Exp Dermatol. 2004;29:133-7.
Grimes PE. Vitiligo: An overview of therapeutic approaches. Dermatol Clin. 1993;11:325-38.
Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJet al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol.2008;159:1051-76
Kostovic K, Nola I, Bucan Z, Situm M. Treatment of vitiligo: current methods and new approaches. Acta Dermatovenerol Croat. 2003;11:163-70.
Kostovic K, Pasic A. New treatment modalities for vitiligo:focus on topical immunomodulators. Drugs. 2005;65:447- 59.
Nordulund JJ, Halder RM, Grimes P. Management of vitiligo. Dermatol Clin. 1993;11:27-33.
Grims PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger Aet al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004;51:52-61.
Kang HY, Choi YM. FK506 increases pigmentation and migration of human melanocytes. Br J Dermatol. 2006;155:1037-40.
Huang H, Wang X, Ding X, Xu Q, Hwang SK, Wang Fet al. Effect and mechanism of tacrolimus on melanogenesis on A375 human melanoma cells. Chin Med J (Engl). 2014;127:2966-71.
Silverberg NB, Lin P, Travis I, Farley-Li J, Mancini AJ, Wagner AMet al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol.2004;51:760-6.
Lo YH, Cheng GS, Huang CC, Chang WY, Wu CS. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo. J Dermatol. 2010;37:125-9.
Whitton M, Ashcroft D, Barrett CW, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev. 2006;1:CD003263.
Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres- Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139:581-5.
Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol. 2004;29:589-92.
Almeida P, Borrego L, Rodriguez-Lopez J, Lujan D, Cameselle D, Hernandez B. Vitiligo: treatment of 12 cases with topical tacrolimus. Actas Dermosifiliogr. 2005;96:159-63.
Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol. 1984;120:631-5.
Agrawal D, Shajil EM, Marfatia YS, Begum R. Study on the antioxidant status of vitiligo patients of different age groups in Baroda. Pigment Cell Res. 2004;17:289- 94.
Tsiskarishvili NV, Tsiskarishvili TI. Antioxidants in vitiligo treatment. Georgian Med News. 2006;134:80-3.
